Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent

Sorin V. Pislaru, Yicheng Ni, Cristina D Pislaru, Hilde Bosmans, Yi Miao, Jan Bogaert, Steven Dymarkowski, Wolfhard Semmler, Guy Marchal, Frans J. Van De Werf

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Background-Gadophrin-2 is a new MRI contrast agent with high affinity for necrotic myocardium. The aim of the study was to evaluate whether noninvasive measurements of infarct size after thrombolysis are possible with gadophrin-2-enhanced MRI. Methods and Results-Coronary artery thrombosis was induced in 3 groups of dogs by the copper-coil technique. Thrombolytic therapy together with aspirin and heparin was initiated after 90 minutes of occlusion. One day (group A), 2 days (group B), or 6 days (group C) after infarction, gadophrin-2 was injected intravenously (50 μmol · kg-1). In vivo T1-weighted segmented turbo-FLASH, in vivo T2-weighted segmented half- Fourier turbo spin echo (HASTE), and T1 and T2-weighted spin-echo MRI of the excised heart were performed 24 hours after gadophrin-2 injection. Regions of strong enhancement were observed on T1-weighted images. Planimetry of short- axis MR images and of corresponding triphenyltetrazolium chloride (TTC)- stained left ventricular (LV) slices showed a close correlation between the enhanced areas and TTC-negative areas for both in vivo (r2=0.98, P < 0.0001; mean difference, 0.9 ± 2.0% [SD] of the LV volume [LVV]) and postmortem (r2 = 0.99, P < 0.0001; mean difference, 0.9 ± 1.4% of LVV) measurements. T2- weighted images overestimated the infarct size by 8.1 ± 5.4% of LVV. The mean infarct size was 10.8 ± 11.6% of LVV (group A), 22.4 ± 11.7% (group B), and 5.1 ± 9.3% (group C). Conclusions-In this animal model, in vivo gadophrin-2-enhanced MRI could precisely determine infarct size after thrombolytic therapy. This technique may be very useful for the noninvasive evaluation of infarct size after reperfusion for AMI.

Original languageEnglish (US)
Pages (from-to)690-696
Number of pages7
JournalCirculation
Volume99
Issue number5
StatePublished - Feb 9 1999
Externally publishedYes

Fingerprint

Contrast Media
Necrosis
Thrombolytic Therapy
Coronary Thrombosis
Infarction
Aspirin
Reperfusion
Heparin
Copper
Coronary Vessels
Myocardium
Animal Models
gadophrin-2
Dogs
Injections
triphenyltetrazolium

Keywords

  • Diagnosis
  • Magnetic resonance imaging
  • Myocardial infarction
  • Thrombolysis

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Pislaru, S. V., Ni, Y., Pislaru, C. D., Bosmans, H., Miao, Y., Bogaert, J., ... Van De Werf, F. J. (1999). Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent. Circulation, 99(5), 690-696.

Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent. / Pislaru, Sorin V.; Ni, Yicheng; Pislaru, Cristina D; Bosmans, Hilde; Miao, Yi; Bogaert, Jan; Dymarkowski, Steven; Semmler, Wolfhard; Marchal, Guy; Van De Werf, Frans J.

In: Circulation, Vol. 99, No. 5, 09.02.1999, p. 690-696.

Research output: Contribution to journalArticle

Pislaru, SV, Ni, Y, Pislaru, CD, Bosmans, H, Miao, Y, Bogaert, J, Dymarkowski, S, Semmler, W, Marchal, G & Van De Werf, FJ 1999, 'Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent', Circulation, vol. 99, no. 5, pp. 690-696.
Pislaru SV, Ni Y, Pislaru CD, Bosmans H, Miao Y, Bogaert J et al. Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent. Circulation. 1999 Feb 9;99(5):690-696.
Pislaru, Sorin V. ; Ni, Yicheng ; Pislaru, Cristina D ; Bosmans, Hilde ; Miao, Yi ; Bogaert, Jan ; Dymarkowski, Steven ; Semmler, Wolfhard ; Marchal, Guy ; Van De Werf, Frans J. / Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent. In: Circulation. 1999 ; Vol. 99, No. 5. pp. 690-696.
@article{cbcd33fc6cf941dab83e4e75aa4ff06b,
title = "Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent",
abstract = "Background-Gadophrin-2 is a new MRI contrast agent with high affinity for necrotic myocardium. The aim of the study was to evaluate whether noninvasive measurements of infarct size after thrombolysis are possible with gadophrin-2-enhanced MRI. Methods and Results-Coronary artery thrombosis was induced in 3 groups of dogs by the copper-coil technique. Thrombolytic therapy together with aspirin and heparin was initiated after 90 minutes of occlusion. One day (group A), 2 days (group B), or 6 days (group C) after infarction, gadophrin-2 was injected intravenously (50 μmol · kg-1). In vivo T1-weighted segmented turbo-FLASH, in vivo T2-weighted segmented half- Fourier turbo spin echo (HASTE), and T1 and T2-weighted spin-echo MRI of the excised heart were performed 24 hours after gadophrin-2 injection. Regions of strong enhancement were observed on T1-weighted images. Planimetry of short- axis MR images and of corresponding triphenyltetrazolium chloride (TTC)- stained left ventricular (LV) slices showed a close correlation between the enhanced areas and TTC-negative areas for both in vivo (r2=0.98, P < 0.0001; mean difference, 0.9 ± 2.0{\%} [SD] of the LV volume [LVV]) and postmortem (r2 = 0.99, P < 0.0001; mean difference, 0.9 ± 1.4{\%} of LVV) measurements. T2- weighted images overestimated the infarct size by 8.1 ± 5.4{\%} of LVV. The mean infarct size was 10.8 ± 11.6{\%} of LVV (group A), 22.4 ± 11.7{\%} (group B), and 5.1 ± 9.3{\%} (group C). Conclusions-In this animal model, in vivo gadophrin-2-enhanced MRI could precisely determine infarct size after thrombolytic therapy. This technique may be very useful for the noninvasive evaluation of infarct size after reperfusion for AMI.",
keywords = "Diagnosis, Magnetic resonance imaging, Myocardial infarction, Thrombolysis",
author = "Pislaru, {Sorin V.} and Yicheng Ni and Pislaru, {Cristina D} and Hilde Bosmans and Yi Miao and Jan Bogaert and Steven Dymarkowski and Wolfhard Semmler and Guy Marchal and {Van De Werf}, {Frans J.}",
year = "1999",
month = "2",
day = "9",
language = "English (US)",
volume = "99",
pages = "690--696",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent

AU - Pislaru, Sorin V.

AU - Ni, Yicheng

AU - Pislaru, Cristina D

AU - Bosmans, Hilde

AU - Miao, Yi

AU - Bogaert, Jan

AU - Dymarkowski, Steven

AU - Semmler, Wolfhard

AU - Marchal, Guy

AU - Van De Werf, Frans J.

PY - 1999/2/9

Y1 - 1999/2/9

N2 - Background-Gadophrin-2 is a new MRI contrast agent with high affinity for necrotic myocardium. The aim of the study was to evaluate whether noninvasive measurements of infarct size after thrombolysis are possible with gadophrin-2-enhanced MRI. Methods and Results-Coronary artery thrombosis was induced in 3 groups of dogs by the copper-coil technique. Thrombolytic therapy together with aspirin and heparin was initiated after 90 minutes of occlusion. One day (group A), 2 days (group B), or 6 days (group C) after infarction, gadophrin-2 was injected intravenously (50 μmol · kg-1). In vivo T1-weighted segmented turbo-FLASH, in vivo T2-weighted segmented half- Fourier turbo spin echo (HASTE), and T1 and T2-weighted spin-echo MRI of the excised heart were performed 24 hours after gadophrin-2 injection. Regions of strong enhancement were observed on T1-weighted images. Planimetry of short- axis MR images and of corresponding triphenyltetrazolium chloride (TTC)- stained left ventricular (LV) slices showed a close correlation between the enhanced areas and TTC-negative areas for both in vivo (r2=0.98, P < 0.0001; mean difference, 0.9 ± 2.0% [SD] of the LV volume [LVV]) and postmortem (r2 = 0.99, P < 0.0001; mean difference, 0.9 ± 1.4% of LVV) measurements. T2- weighted images overestimated the infarct size by 8.1 ± 5.4% of LVV. The mean infarct size was 10.8 ± 11.6% of LVV (group A), 22.4 ± 11.7% (group B), and 5.1 ± 9.3% (group C). Conclusions-In this animal model, in vivo gadophrin-2-enhanced MRI could precisely determine infarct size after thrombolytic therapy. This technique may be very useful for the noninvasive evaluation of infarct size after reperfusion for AMI.

AB - Background-Gadophrin-2 is a new MRI contrast agent with high affinity for necrotic myocardium. The aim of the study was to evaluate whether noninvasive measurements of infarct size after thrombolysis are possible with gadophrin-2-enhanced MRI. Methods and Results-Coronary artery thrombosis was induced in 3 groups of dogs by the copper-coil technique. Thrombolytic therapy together with aspirin and heparin was initiated after 90 minutes of occlusion. One day (group A), 2 days (group B), or 6 days (group C) after infarction, gadophrin-2 was injected intravenously (50 μmol · kg-1). In vivo T1-weighted segmented turbo-FLASH, in vivo T2-weighted segmented half- Fourier turbo spin echo (HASTE), and T1 and T2-weighted spin-echo MRI of the excised heart were performed 24 hours after gadophrin-2 injection. Regions of strong enhancement were observed on T1-weighted images. Planimetry of short- axis MR images and of corresponding triphenyltetrazolium chloride (TTC)- stained left ventricular (LV) slices showed a close correlation between the enhanced areas and TTC-negative areas for both in vivo (r2=0.98, P < 0.0001; mean difference, 0.9 ± 2.0% [SD] of the LV volume [LVV]) and postmortem (r2 = 0.99, P < 0.0001; mean difference, 0.9 ± 1.4% of LVV) measurements. T2- weighted images overestimated the infarct size by 8.1 ± 5.4% of LVV. The mean infarct size was 10.8 ± 11.6% of LVV (group A), 22.4 ± 11.7% (group B), and 5.1 ± 9.3% (group C). Conclusions-In this animal model, in vivo gadophrin-2-enhanced MRI could precisely determine infarct size after thrombolytic therapy. This technique may be very useful for the noninvasive evaluation of infarct size after reperfusion for AMI.

KW - Diagnosis

KW - Magnetic resonance imaging

KW - Myocardial infarction

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=0033537504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033537504&partnerID=8YFLogxK

M3 - Article

VL - 99

SP - 690

EP - 696

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 5

ER -